RG6333 / Roche 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RG6333 / Roche
BP43131, NCT05219513: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated
1
53
Europe, US, RoW
RO7443904, Glofitamab, RO7082859, Obinutuzumab, Tocilizumab, Actemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
07/24
07/24

Download Options